Jayson Hardcastle
Affiliations: | Ohio State University, Columbus, Columbus, OH |
Google:
"Jayson Hardcastle"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Bolyard CM, Meisen WH, Banasavadi-Siddegowda Y, et al. (2016) BAI1 Orchestrates Macrophage Inflammatory Response to HSV Infection- implications for Oncolytic Viral Therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Hardcastle J, Mills L, Malo CS, et al. (2016) Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment. Neuro-Oncology |
| Meisen WH, Wohleb ES, Jaime-Ramirez AC, et al. (2015) The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 3274-85 |
| Wojton J, Meisen WH, Jacob NK, et al. (2014) SapC-DOPS-induced lysosomal cell death synergizes with TMZ in glioblastoma. Oncotarget. 5: 9703-9 |
| Alvarez-Breckenridge CA, Yu J, Price R, et al. (2012) NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. Nature Medicine. 18: 1827-34 |
| Chiocca EA, Aguilar LK, Bell SD, et al. (2011) Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3611-9 |
| Hardcastle J, Kurozumi K, Dmitrieva N, et al. (2010) Enhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1 Molecular Therapy. 18: 285-294 |
| Kurozumi K, Hardcastle J, Thakur R, et al. (2008) Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 1382-91 |
| Kurozumi K, Hardcastle J, Thakur R, et al. (2007) Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. Journal of the National Cancer Institute. 99: 1768-81 |
| Hardcastle J, Kurozumi K, Chiocca EA, et al. (2007) Oncolytic viruses driven by tumor-specific promoters. Current Cancer Drug Targets. 7: 181-9 |